Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 39 entries
Sorted by: Best Match Show Resources per page
(E)-3-(2,6-Dichloro-phen-yl)-1-(4-methoxy-phen-yl)prop-2-en-1-one.

Acta crystallographica. Section E, Structure reports online

Benmekhbi L, Belhouas R, Bouacida S, Mosbah S, Bencharif L.
PMID: 21582775
Acta Crystallogr Sect E Struct Rep Online. 2009 Jun 06;65:o1472-3. doi: 10.1107/S1600536809020145.

In the title compound, C(16)H(12)Cl(2)O(2), the dichloro-phenyl and methoxy-phenyl groups are linked by a prop-2-en-1-one group. The C=C double bond is trans configured. The mol-ecule is not planar, as can be seen from the dihedral angle of 6.21 (7)°...

Cite
Benmekhbi L, Belhouas R, Bouacida S, et al. (E)-3-(2,6-Dichloro-phen-yl)-1-(4-methoxy-phen-yl)prop-2-en-1-one. Acta Crystallogr Sect E Struct Rep Online. 2009;65:o1472-3doi: 10.1107/S1600536809020145.
Benmekhbi, L., Belhouas, R., Bouacida, S., Mosbah, S., & Bencharif, L. (2009). (E)-3-(2,6-Dichloro-phen-yl)-1-(4-methoxy-phen-yl)prop-2-en-1-one. Acta crystallographica. Section E, Structure reports online, 65o1472-3. https://doi.org/10.1107/S1600536809020145
Benmekhbi, Lotfi, et al. "(E)-3-(2,6-Dichloro-phen-yl)-1-(4-methoxy-phen-yl)prop-2-en-1-one." Acta crystallographica. Section E, Structure reports online vol. 65 (2009): o1472-3. doi: https://doi.org/10.1107/S1600536809020145
Benmekhbi L, Belhouas R, Bouacida S, Mosbah S, Bencharif L. (E)-3-(2,6-Dichloro-phen-yl)-1-(4-methoxy-phen-yl)prop-2-en-1-one. Acta Crystallogr Sect E Struct Rep Online. 2009 Jun 06;65:o1472-3. doi: 10.1107/S1600536809020145. PMID: 21582775; PMCID: PMC2969433.
Copy Download .nbib Format: NLM
Full mouth rehabilitation with implant-supported prostheses for severe periodontitis: a case report.

The open dentistry journal

Bencharit S, Schardt-Sacco D, Border MB, Barbaro CP.
PMID: 21339901
Open Dent J. 2010 Aug 13;4:165-71. doi: 10.2174/1874210601004010165.

Oral rehabilitation for a patient with severe loss of alveolar bone and soft tissue resulting from severe periodontitis presents a challenge to clinicians. Replacing loosening natural teeth with fixed prostheses supported by dental implants often requires either gingival surgery...

Cite
Bencharit S, Schardt-Sacco D, Border MB, et al. Full mouth rehabilitation with implant-supported prostheses for severe periodontitis: a case report. Open Dent J. 2010;4:165-71doi: 10.2174/1874210601004010165.
Bencharit, S., Schardt-Sacco, D., Border, M. B., & Barbaro, C. P. (2010). Full mouth rehabilitation with implant-supported prostheses for severe periodontitis: a case report. The open dentistry journal, 4165-71. https://doi.org/10.2174/1874210601004010165
Bencharit, Sompop, et al. "Full mouth rehabilitation with implant-supported prostheses for severe periodontitis: a case report." The open dentistry journal vol. 4 (2010): 165-71. doi: https://doi.org/10.2174/1874210601004010165
Bencharit S, Schardt-Sacco D, Border MB, Barbaro CP. Full mouth rehabilitation with implant-supported prostheses for severe periodontitis: a case report. Open Dent J. 2010 Aug 13;4:165-71. doi: 10.2174/1874210601004010165. PMID: 21339901; PMCID: PMC3041016.
Copy Download .nbib Format: NLM
The Effect of Heteroatom Doping on Nickel Cobalt Oxide Electrocatalysts for Oxygen Evolution and Reduction Reactions.

ChemPlusChem

Belkessam C, Bencherif S, Mechouet M, Idiri N, Ghilane J.
PMID: 32779395
Chempluschem. 2020 Aug;85(8):1710-1718. doi: 10.1002/cplu.202000436.

The synthesis of nickel cobalt oxide materials and their electrocatalytic performance toward the oxygen reduction and evolution reactions are reported. Nickel cobalt oxides were synthesized in a sol-gel process with different precursors, namely nitrate, sulfate, and chloride. Structural analyses...

Cite
Belkessam C, Bencherif S, Mechouet M, et al. The Effect of Heteroatom Doping on Nickel Cobalt Oxide Electrocatalysts for Oxygen Evolution and Reduction Reactions. Chempluschem. 2020;85(8):1710-1718doi: 10.1002/cplu.202000436.
Belkessam, C., Bencherif, S., Mechouet, M., Idiri, N., & Ghilane, J. (2020). The Effect of Heteroatom Doping on Nickel Cobalt Oxide Electrocatalysts for Oxygen Evolution and Reduction Reactions. ChemPlusChem, 85(8), 1710-1718. https://doi.org/10.1002/cplu.202000436
Belkessam, Celia, et al. "The Effect of Heteroatom Doping on Nickel Cobalt Oxide Electrocatalysts for Oxygen Evolution and Reduction Reactions." ChemPlusChem vol. 85,8 (2020): 1710-1718. doi: https://doi.org/10.1002/cplu.202000436
Belkessam C, Bencherif S, Mechouet M, Idiri N, Ghilane J. The Effect of Heteroatom Doping on Nickel Cobalt Oxide Electrocatalysts for Oxygen Evolution and Reduction Reactions. Chempluschem. 2020 Aug;85(8):1710-1718. doi: 10.1002/cplu.202000436. PMID: 32779395.
Copy Download .nbib Format: NLM
Implant site preparation application of injectable platelet-rich fibrin for vertical and horizontal bone regeneration: A clinical report.

The Journal of oral implantology

Thanasrisuebwong P, Kiattavorncharoen S, Deeb GR, Bencharit S.
PMID: 33270878
J Oral Implantol. 2020 Dec 03; doi: 10.1563/aaid-joi-D-20-00031. Epub 2020 Dec 03.

Guided bone regeneration (GBR) using a combined injectable platelet-rich fibrin (i-PRF), leukocyte- and platelet-rich fibrin (L-PRF) and biocompatible bone substitute materials, is a convenient and effective method to augment a combined vertical and horizontal bone defect. This approach can...

Cite
Thanasrisuebwong P, Kiattavorncharoen S, Deeb GR, et al. Implant site preparation application of injectable platelet-rich fibrin for vertical and horizontal bone regeneration: A clinical report. J Oral Implantol. 2020;doi: 10.1563/aaid-joi-D-20-00031.
Thanasrisuebwong, P., Kiattavorncharoen, S., Deeb, G. R., & Bencharit, S. (2020). Implant site preparation application of injectable platelet-rich fibrin for vertical and horizontal bone regeneration: A clinical report. The Journal of oral implantology, . https://doi.org/10.1563/aaid-joi-D-20-00031
Thanasrisuebwong, Prakan, et al. "Implant site preparation application of injectable platelet-rich fibrin for vertical and horizontal bone regeneration: A clinical report." The Journal of oral implantology vol. (2020). doi: https://doi.org/10.1563/aaid-joi-D-20-00031
Thanasrisuebwong P, Kiattavorncharoen S, Deeb GR, Bencharit S. Implant site preparation application of injectable platelet-rich fibrin for vertical and horizontal bone regeneration: A clinical report. J Oral Implantol. 2020 Dec 03; doi: 10.1563/aaid-joi-D-20-00031. Epub 2020 Dec 03. PMID: 33270878.
Copy Download .nbib Format: NLM
The Combined Prognostic Significance of Alkaline Phosphatase and Intracranial Arterial Calcifications in Hemodialysis Patients.

American journal of nephrology

Erez D, Fanadka F, Benchetrit S, Cohen-Hagai K.
PMID: 34569494
Am J Nephrol. 2021;52(9):763-770. doi: 10.1159/000518399. Epub 2021 Sep 17.

INTRODUCTION: The prevalence of intracranial arterial calcification (ICAC) in maintenance hemodialysis (MHD) patients is about 90%, and its severity is correlated with age, hemodialysis vintage, and mineral bone disease. Elevated concentrations of calcium and phosphorus are not sufficient for...

Cite
Erez D, Fanadka F, Benchetrit S, et al. The Combined Prognostic Significance of Alkaline Phosphatase and Intracranial Arterial Calcifications in Hemodialysis Patients. Am J Nephrol. 2021;52(9):763-770doi: 10.1159/000518399.
Erez, D., Fanadka, F., Benchetrit, S., & Cohen-Hagai, K. (2021). The Combined Prognostic Significance of Alkaline Phosphatase and Intracranial Arterial Calcifications in Hemodialysis Patients. American journal of nephrology, 52(9), 763-770. https://doi.org/10.1159/000518399
Erez, Daniel, et al. "The Combined Prognostic Significance of Alkaline Phosphatase and Intracranial Arterial Calcifications in Hemodialysis Patients." American journal of nephrology vol. 52,9 (2021): 763-770. doi: https://doi.org/10.1159/000518399
Erez D, Fanadka F, Benchetrit S, Cohen-Hagai K. The Combined Prognostic Significance of Alkaline Phosphatase and Intracranial Arterial Calcifications in Hemodialysis Patients. Am J Nephrol. 2021;52(9):763-770. doi: 10.1159/000518399. Epub 2021 Sep 17. PMID: 34569494; PMCID: PMC8686705.
Copy Download .nbib Format: NLM
The Effect of Admission Renal Function on the Treatment and Outcome of Patients with Acute Coronary Syndrome.

Cardiorenal medicine

Rozenbaum Z, Benchetrit S, Minha S, Neuman Y, Shlezinger M, Goldenberg I, Mosseri M, Pereg D.
PMID: 28736557
Cardiorenal Med. 2017 Jun;7(3):169-178. doi: 10.1159/000455239. Epub 2017 Feb 17.

BACKGROUND: Chronic kidney disease is a frequent comorbidity among patients with acute coronary syndrome (ACS). We aimed to evaluate treatment characteristics in ACS patients according to their renal function and to assess the effect of differences in therapy on...

Cite
Rozenbaum Z, Benchetrit S, Minha S, et al. The Effect of Admission Renal Function on the Treatment and Outcome of Patients with Acute Coronary Syndrome. Cardiorenal Med. 2017;7(3):169-178doi: 10.1159/000455239.
Rozenbaum, Z., Benchetrit, S., Minha, S., Neuman, Y., Shlezinger, M., Goldenberg, I., Mosseri, M., & Pereg, D. (2017). The Effect of Admission Renal Function on the Treatment and Outcome of Patients with Acute Coronary Syndrome. Cardiorenal medicine, 7(3), 169-178. https://doi.org/10.1159/000455239
Rozenbaum, Zach, et al. "The Effect of Admission Renal Function on the Treatment and Outcome of Patients with Acute Coronary Syndrome." Cardiorenal medicine vol. 7,3 (2017): 169-178. doi: https://doi.org/10.1159/000455239
Rozenbaum Z, Benchetrit S, Minha S, Neuman Y, Shlezinger M, Goldenberg I, Mosseri M, Pereg D. The Effect of Admission Renal Function on the Treatment and Outcome of Patients with Acute Coronary Syndrome. Cardiorenal Med. 2017 Jun;7(3):169-178. doi: 10.1159/000455239. Epub 2017 Feb 17. PMID: 28736557; PMCID: PMC5511990.
Copy Download .nbib Format: NLM
Octa-kis[2,2',5,5'-tetra-thia-fulvalenium(0.5+)] bis-[hexa-molybdate(2-)] acetonitrile solvate.

Acta crystallographica. Section E, Structure reports online

Zebiri I, Anak B, Djebli Y, Boufas S, Bencharif L.
PMID: 21577422
Acta Crystallogr Sect E Struct Rep Online. 2009 Aug 12;65:m1063-4. doi: 10.1107/S1600536809031092.

The asymmetric unit of the title compound, (C(6)H(4)S(4))(8)[Mo(6)O(19)](2)·CH(3)CN, contains two halves of two centrosymmetric [Mo(6)O(19)](2-) hexa-molybdate anions, which are each built up from six distorted MoO(6) octa-hedra sharing common edges and one common vertex at the central O atom,...

Cite
Zebiri I, Anak B, Djebli Y, et al. Octa-kis[2,2',5,5'-tetra-thia-fulvalenium(0.5+)] bis-[hexa-molybdate(2-)] acetonitrile solvate. Acta Crystallogr Sect E Struct Rep Online. 2009;65:m1063-4doi: 10.1107/S1600536809031092.
Zebiri, I., Anak, B., Djebli, Y., Boufas, S., & Bencharif, L. (2009). Octa-kis[2,2',5,5'-tetra-thia-fulvalenium(0.5+)] bis-[hexa-molybdate(2-)] acetonitrile solvate. Acta crystallographica. Section E, Structure reports online, 65m1063-4. https://doi.org/10.1107/S1600536809031092
Zebiri, Ikram, et al. "Octa-kis[2,2',5,5'-tetra-thia-fulvalenium(0.5+)] bis-[hexa-molybdate(2-)] acetonitrile solvate." Acta crystallographica. Section E, Structure reports online vol. 65 (2009): m1063-4. doi: https://doi.org/10.1107/S1600536809031092
Zebiri I, Anak B, Djebli Y, Boufas S, Bencharif L. Octa-kis[2,2',5,5'-tetra-thia-fulvalenium(0.5+)] bis-[hexa-molybdate(2-)] acetonitrile solvate. Acta Crystallogr Sect E Struct Rep Online. 2009 Aug 12;65:m1063-4. doi: 10.1107/S1600536809031092. PMID: 21577422; PMCID: PMC2970104.
Copy Download .nbib Format: NLM
A treatment protocol for restoring occlusal vertical dimension using an overlay removable partial denture as an alternative to extensive fixed restorations: a clinical report.

The open dentistry journal

Patel MB, Bencharit S.
PMID: 19915723
Open Dent J. 2009 Oct 30;3:213-8. doi: 10.2174/1874210600903010213.

Treatment options for patients with severe attrition resulting in reduced occlusal vertical dimension are often limited to fixed prosthesis to reestablish proper occlusal vertical dimension and functional occlusion. In some cases such as when there are limited finances, minimal...

Cite
Patel MB, Bencharit S. A treatment protocol for restoring occlusal vertical dimension using an overlay removable partial denture as an alternative to extensive fixed restorations: a clinical report. Open Dent J. 2009;3:213-8doi: 10.2174/1874210600903010213.
Patel, M. B., & Bencharit, S. (2009). A treatment protocol for restoring occlusal vertical dimension using an overlay removable partial denture as an alternative to extensive fixed restorations: a clinical report. The open dentistry journal, 3213-8. https://doi.org/10.2174/1874210600903010213
Patel, Mit B, and Bencharit, Sompop. "A treatment protocol for restoring occlusal vertical dimension using an overlay removable partial denture as an alternative to extensive fixed restorations: a clinical report." The open dentistry journal vol. 3 (2009): 213-8. doi: https://doi.org/10.2174/1874210600903010213
Patel MB, Bencharit S. A treatment protocol for restoring occlusal vertical dimension using an overlay removable partial denture as an alternative to extensive fixed restorations: a clinical report. Open Dent J. 2009 Oct 30;3:213-8. doi: 10.2174/1874210600903010213. PMID: 19915723; PMCID: PMC2776309.
Copy Download .nbib Format: NLM
Ammonium tris-(tetra-ethyl-ammonium) hexa-cosa-oxidoocta-molybdate.

Acta crystallographica. Section E, Structure reports online

Zebiri I, Bencharif L, Direm A, Bencharif M, Benali-Cherif N.
PMID: 21201863
Acta Crystallogr Sect E Struct Rep Online. 2008 Feb 15;64:m474-5. doi: 10.1107/S1600536808004182.

The structure of the title compound, NH(4)(C(8)H(20)N)(3)[Mo(8)O(26)], is built up by discrete cations and anions, with two formula units in the asymmetric unit. The β-octa-molybdate anions are linked to the ammonium cations via N-H⋯O hydrogen bonding involving terminal oxide...

Cite
Zebiri I, Bencharif L, Direm A, et al. Ammonium tris-(tetra-ethyl-ammonium) hexa-cosa-oxidoocta-molybdate. Acta Crystallogr Sect E Struct Rep Online. 2008;64:m474-5doi: 10.1107/S1600536808004182.
Zebiri, I., Bencharif, L., Direm, A., Bencharif, M., & Benali-Cherif, N. (2008). Ammonium tris-(tetra-ethyl-ammonium) hexa-cosa-oxidoocta-molybdate. Acta crystallographica. Section E, Structure reports online, 64m474-5. https://doi.org/10.1107/S1600536808004182
Zebiri, Ikram, et al. "Ammonium tris-(tetra-ethyl-ammonium) hexa-cosa-oxidoocta-molybdate." Acta crystallographica. Section E, Structure reports online vol. 64 (2008): m474-5. doi: https://doi.org/10.1107/S1600536808004182
Zebiri I, Bencharif L, Direm A, Bencharif M, Benali-Cherif N. Ammonium tris-(tetra-ethyl-ammonium) hexa-cosa-oxidoocta-molybdate. Acta Crystallogr Sect E Struct Rep Online. 2008 Feb 15;64:m474-5. doi: 10.1107/S1600536808004182. PMID: 21201863; PMCID: PMC2960748.
Copy Download .nbib Format: NLM
Cost-effectiveness analysis of rifaximin-α administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France.

Therapeutic advances in gastroenterology

Kabeshova A, Ben Hariz S, Tsakeu E, Benamouzig R, Launois R.
PMID: 27366216
Therap Adv Gastroenterol. 2016 Jul;9(4):473-82. doi: 10.1177/1756283X16644249. Epub 2016 May 01.

BACKGROUND: Hepatic encephalopathy (HE) is a complex neuropsychiatric syndrome that occurs most often in a context of acute or chronic liver disease. Despite the seriousness of the pathology, only a few treatments have been developed for improving its management....

Cite
Kabeshova A, Ben Hariz S, Tsakeu E, et al. Cost-effectiveness analysis of rifaximin-α administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France. Therap Adv Gastroenterol. 2016;9(4):473-82doi: 10.1177/1756283X16644249.
Kabeshova, A., Ben Hariz, S., Tsakeu, E., Benamouzig, R., & Launois, R. (2016). Cost-effectiveness analysis of rifaximin-α administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France. Therapeutic advances in gastroenterology, 9(4), 473-82. https://doi.org/10.1177/1756283X16644249
Kabeshova, Anastasiia, et al. "Cost-effectiveness analysis of rifaximin-α administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France." Therapeutic advances in gastroenterology vol. 9,4 (2016): 473-82. doi: https://doi.org/10.1177/1756283X16644249
Kabeshova A, Ben Hariz S, Tsakeu E, Benamouzig R, Launois R. Cost-effectiveness analysis of rifaximin-α administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France. Therap Adv Gastroenterol. 2016 Jul;9(4):473-82. doi: 10.1177/1756283X16644249. Epub 2016 May 01. PMID: 27366216; PMCID: PMC4913340.
Copy Download .nbib Format: NLM
Elevated expression of galectin-3, thioredoxin and thioredoxin interacting protein in preeclampsia.

Pregnancy hypertension

Farladansky-Gershnabel S, Heusler I, Biron-Shental T, Shechter-Maor G, Amiel A, Kidron D, Weisz A, Einbinder Y, Cohen-Hagai K, Benchetrit S, Zitman-Gal T.
PMID: 34700108
Pregnancy Hypertens. 2021 Dec;26:95-101. doi: 10.1016/j.preghy.2021.10.003. Epub 2021 Oct 13.

OBJECTIVES: Preeclampsia (PE) is a pregnancy-related syndrome characterized by the onset of hypertension and proteinuria that can lead to end-organ dysfunction. Galectin-3 (Gal-3) is involved in cell growth, differentiation, inflammation and fibrosis. Thioredoxin (TXN) acts as antioxidant enzyme in...

Cite
Farladansky-Gershnabel S, Heusler I, Biron-Shental T, et al. Elevated expression of galectin-3, thioredoxin and thioredoxin interacting protein in preeclampsia. Pregnancy Hypertens. 2021;26:95-101doi: 10.1016/j.preghy.2021.10.003.
Farladansky-Gershnabel, S., Heusler, I., Biron-Shental, T., Shechter-Maor, G., Amiel, A., Kidron, D., Weisz, A., Einbinder, Y., Cohen-Hagai, K., Benchetrit, S., & Zitman-Gal, T. (2021). Elevated expression of galectin-3, thioredoxin and thioredoxin interacting protein in preeclampsia. Pregnancy hypertension, 2695-101. https://doi.org/10.1016/j.preghy.2021.10.003
Farladansky-Gershnabel, Sivan, et al. "Elevated expression of galectin-3, thioredoxin and thioredoxin interacting protein in preeclampsia." Pregnancy hypertension vol. 26 (2021): 95-101. doi: https://doi.org/10.1016/j.preghy.2021.10.003
Farladansky-Gershnabel S, Heusler I, Biron-Shental T, Shechter-Maor G, Amiel A, Kidron D, Weisz A, Einbinder Y, Cohen-Hagai K, Benchetrit S, Zitman-Gal T. Elevated expression of galectin-3, thioredoxin and thioredoxin interacting protein in preeclampsia. Pregnancy Hypertens. 2021 Dec;26:95-101. doi: 10.1016/j.preghy.2021.10.003. Epub 2021 Oct 13. PMID: 34700108.
Copy Download .nbib Format: NLM
Presence of galectin-3 in peritoneal dialysate. Does it have a role in the peritoneal membrane inflammatory process?.

Nephrology (Carlton, Vic.)

Einbinder Y, Siboni A, Zaidenstein S, Cohen-Hagai K, Benchetrit S, Zitman-Gal T.
PMID: 34611952
Nephrology (Carlton). 2022 Jan;27(1):104-108. doi: 10.1111/nep.13981. Epub 2021 Oct 05.

Peritoneal dialysis (PD) causes structural and functional changes in the peritoneal membrane, which are attributed to local inflammatory process. This study assessed the presence of galectin-3 (Gal-3), a known inflammatory modulator, in dialysate effluent and correlated its levels with...

Cite
Einbinder Y, Siboni A, Zaidenstein S, et al. Presence of galectin-3 in peritoneal dialysate. Does it have a role in the peritoneal membrane inflammatory process?. Nephrology (Carlton). 2021;27(1):104-108doi: 10.1111/nep.13981.
Einbinder, Y., Siboni, A., Zaidenstein, S., Cohen-Hagai, K., Benchetrit, S., & Zitman-Gal, T. (2022). Presence of galectin-3 in peritoneal dialysate. Does it have a role in the peritoneal membrane inflammatory process?. Nephrology (Carlton, Vic.), 27(1), 104-108. https://doi.org/10.1111/nep.13981
Einbinder, Yael, et al. "Presence of galectin-3 in peritoneal dialysate. Does it have a role in the peritoneal membrane inflammatory process?." Nephrology (Carlton, Vic.) vol. 27,1 (2022): 104-108. doi: https://doi.org/10.1111/nep.13981
Einbinder Y, Siboni A, Zaidenstein S, Cohen-Hagai K, Benchetrit S, Zitman-Gal T. Presence of galectin-3 in peritoneal dialysate. Does it have a role in the peritoneal membrane inflammatory process?. Nephrology (Carlton). 2022 Jan;27(1):104-108. doi: 10.1111/nep.13981. Epub 2021 Oct 05. PMID: 34611952.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 39 entries